{"title":"HHS OIG:Medicare Advantage、Medicaid 和医生限制使用 MOUD","authors":"Alison Knopf","doi":"10.1002/adaw.34278","DOIUrl":null,"url":null,"abstract":"<p>Patients with insurance coverage under Medicare — in particular, Medicare Advantage — or Medicaid are less likely to receive medications for opioid use disorder (MOUD) because providers are just unwilling to treat them, according to a report released last month by the federal Department of Health and Human Services (HHS) Office of Inspector General (OIG). The report repeatedly refers to “behavioral health,” so in this article, we do too.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"36 39","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HHS OIG: Medicare Advantage, Medicaid, and physicians limit access to MOUD\",\"authors\":\"Alison Knopf\",\"doi\":\"10.1002/adaw.34278\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Patients with insurance coverage under Medicare — in particular, Medicare Advantage — or Medicaid are less likely to receive medications for opioid use disorder (MOUD) because providers are just unwilling to treat them, according to a report released last month by the federal Department of Health and Human Services (HHS) Office of Inspector General (OIG). The report repeatedly refers to “behavioral health,” so in this article, we do too.</p>\",\"PeriodicalId\":100073,\"journal\":{\"name\":\"Alcoholism & Drug Abuse Weekly\",\"volume\":\"36 39\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alcoholism & Drug Abuse Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34278\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcoholism & Drug Abuse Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34278","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
HHS OIG: Medicare Advantage, Medicaid, and physicians limit access to MOUD
Patients with insurance coverage under Medicare — in particular, Medicare Advantage — or Medicaid are less likely to receive medications for opioid use disorder (MOUD) because providers are just unwilling to treat them, according to a report released last month by the federal Department of Health and Human Services (HHS) Office of Inspector General (OIG). The report repeatedly refers to “behavioral health,” so in this article, we do too.